Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION
**DOSAGE AND ADMINISTRATION** The recommended dose is one drop of ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% in the affected eye(s) three times daily, approximately 8 hours apart. If more than one topical ophthalmic drug is to be used, the different drugs should be instilled at least 5 minutes apart.
OPHTHALMIC
Medical Information
**INDICATIONS AND USAGE** ALPHAGAN® P is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
**CONTRAINDICATIONS** ALPHAGAN® P is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication. It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and contraindicated in neonates and infants (children under the age of 2 years).
S01EA05
brimonidine
Manufacturer Information
ABBVIE PTE. LTD.
ALLERGAN SALES LLC
Active Ingredients
Documents
Package Inserts
Alphagan P Ophthalmic Solution PI.pdf
Approved: June 14, 2017